FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:284-287 July 26, 2001 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Ellis, C. N. PubMed Citation

Psoriasis is an inflammatory skin disorder that affects about 1 to 3 percent of persons throughout the world.¹ Although most persons with plaque psoriasis have mild or moderate disease that affects small areas of the skin, some have extensive disease that is severe and difficult to treat. It is not known why some persons have severe disease and others have mild involvement.

One theory of the pathogenesis of psoriasis is that it is primarily a disorder that involves the proliferation of keratinocytes, with secondary inflammation. Supporters of this concept have noted defects in cytokine expression, intracellular signaling, and polyamines, as . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Nestle, F. O., Kaplan, D. H., Barker, J. (2009). Psoriasis. NEJM 361: 496-509 [Full Text]  
• Hutmacher, M. M., Nestorov, I., Ludden, T., Zitnik, R., Banfield, C. (2007). Modeling the Exposure-Response Relationship of Etanercept in the Treatment of Patients With Chronic Moderate to Severe Plaque Psoriasis. J Clin Pharmacol 47: 238-248 [Abstract] [Full Text]  
• Schön, M. P., Boehncke, W.-H. (2005). Psoriasis. NEJM 352: 1899-1912 [Full Text]  
• Schwartz, R. S. (2003). Diversity of the Immune Repertoire and Immunoregulation. NEJM 348: 1017-1026 [Full Text]  
• Millard, T. P., Birch, K. E., Young, E. R., Haserick, J. R., Hanauer, L., Ellis, C. N., Krueger, G. G., Granstein, R. D. (2001). Treatment of Plaque Psoriasis. NEJM 345: 1853-1855 [Full Text]  
• (2001). Alefacept Targets Memory Effector T Cells and Improves Psoriasis. Journal Watch Dermatology 2001: 3-3 [Full Text]